The purpose of this study is to determine if a combination of investigational agents is safe
to give to people with small cell lung cancer (SCLC) after standard chemotherapy has been
attempted. Subjects enrolled in this trial will receive 3 investigational drugs: SGI-110
(guadecitabine), durvalumab (MEDI4736) and tremelimumab.